Glial Activation Cx43 SGC Review — anchor for CA-I2 satellite-glial calcium intersection
One-paragraph summary
Comprehensive review of glia-neuronal dysregulation in chronic pain, with explicit treatment of three glial cell populations: spinal microglia, spinal astrocytes, and peripheral satellite glial cells (SGCs). The review names specific mechanisms at each population: microglia release BDNF/IL-1β/TNF-α disrupting dorsal-horn chloride homeostasis and inducing disinhibition; astrocytes have impaired glutamate clearance via EAAT2 with CXCL1 + ATP release driving sensitization; and SGCs in peripheral ganglia exhibit connexin-43-mediated coupling that produces hyperexcitability — directly the I-2 intersection (P2X7 + Cx43 Ca²⁺ waves in SGC/DRG) in the project's calcium dysregulation hypothesis v0.2. The review provides mechanism vocabulary and citations for the calcium-intersection framework and validates the SGC×Cx43×Ca²⁺ axis as a recognized chronic-pain mechanism, not project-internal speculation.
Claims as triples
- microglia — release → BDNF [evidence: review consolidation; confidence: established (well-documented in dorsal-horn literature)]
- microglia — release → IL_1_beta [evidence: review; confidence: established]
- microglia — release → TNF_alpha [evidence: review; confidence: established]
- dorsal_horn_chloride_homeostasis — disrupted_by → microglial_BDNF_release [evidence: review; confidence: established]
- astrocyte — impaired_in → glutamate_clearance_EAAT2 [evidence: review; confidence: established]
- satellite_glia — coupled_via → connexin_43 [evidence: review; confidence: established — directly anchors CA-I2]
- connexin_43_satellite_glia_coupling — causes → DRG_hyperexcitability [evidence: review; confidence: established]
- DRG_hyperexcitability — drives → neuropathic_orofacial_pain [evidence: review; confidence: emerging — review-cited primary work]
- satellite_glia_Cx43_coupling — contributes_to → peripheral_neuroinflammation [evidence: review; confidence: established]
Methods note
Narrative + integrative review. Not systematic. Quality of review-tier evidence depends on quality of cited primary work. The Cx43-SGC mechanism in particular is anchored by primary work from Hanani's group (mouse/rat DRG explants, Cx43 knockout, gap-junction blocker studies) and Krock et al's FM-direct SGC work — both already in this project's ontology and intake history. So this review consolidates a well-established mechanism rather than introducing new claims.
Limitations
- Narrative review with author selection of primary studies — possible citation-bias
- Aggregates across diverse pain models (neuropathic, inflammatory, orofacial) which may not all generalize to FM
- Does not include systematic literature search methodology
- Does not include the choroidal MC mechanism or HERV-mtDNA mechanism — narrower scope than the project's full chain model
Open questions raised
- Q-Ca-17 (new): What is the within-FM evidence of Cx43-SGC coupling specifically? Krock 2023 establishes anti-SGC IgG in FM; this review establishes Cx43-coupling as the mechanism that makes SGC dysfunction pathogenic. The unanswered question: in FM specifically (not generic chronic pain), is Cx43-SGC coupling elevated, and does anti-SGC IgG modulate Cx43-coupling specifically?
- Q-Ca-18 (new): Are Cx43 hemichannel blockers (carbenoxolone, mefloquine, peptide5, INI-0602) a viable cure-path arm for FM? The review cites preclinical efficacy in neuropathic-pain models; FM-direct trial evidence is absent.
- Q-Ca-19 (new): How does the SGC Cx43 coupling intersect with mast cells in the DRG (the H1×H2 unified mechanism via MRGPRX2)? Cx43 Ca²⁺ wave propagation might amplify a localized MC degranulation event into a coordinated SGC activation pattern, mechanistically linking H2 (MC) and CA-I2 (SGC Ca²⁺) intersections.
Triangulation notes
- Directly anchors CA-I2 (P2X7 + Cx43 Ca²⁺ waves in satellite glia / DRG): provides external (non-project-internal) validation of the I-2 intersection as a recognized chronic-pain mechanism. Promotes CA-I2 from project-internal hypothesis to consensus-tier mechanism whose FM-specificity is now the open question.
- Strengthens the H1 (autoimmune-microbiome) chain at the SGC effector node: Krock 2023 (anti-SGC IgG in FM) + this review (Cx43-mediated SGC pathogenicity) jointly support a mechanism where FM-IgG → SGC → Cx43-mediated DRG hyperexcitability. The Cx43 step is now well-documented; the next missing piece is whether FM-IgG specifically modulates Cx43 expression or function in SGCs.
- Adds Cx43 hemichannel blockers as cure-path arm candidate: carbenoxolone, mefloquine, peptide5, INI-0602 are listed in the review's therapeutic-strategy section. These need to be evaluated against the project's cure-path-arm-decisions framework — currently absent.
- Doesn't reshape mechanism-map but supplies citations: the project's mechanism map already includes SGC × Cx43 × DRG hyperexcitability via the calcium-dysregulation v0.2 synthesis; this review supplies the consolidating citation.
Bridges
- No new bridges, but closes a project-internal vs external-evidence gap for CA-I2: the I-2 intersection was previously project-derived from primary papers; this review consolidates it as recognized mechanism.
Cure-path-arm implications
- Add Cx43 hemichannel blockers (carbenoxolone, mefloquine, peptide5, INI-0602) as a candidate cure-path arm — should be evaluated in cure-path-arm-decisions document at "watchlist" tier pending FM-direct evidence.